Literature DB >> 2225711

Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition.

R L Lalonde1, T L O'Rear, I W Wainer, K D Drda, V L Herring, M B Bottorff.   

Abstract

Labetalol pharmacokinetics and pharmacodynamics were evaluated in nine subjects before and during enzyme inhibition with cimetidine. Pharmacologic response was assessed by use of standardized treadmill tests during 24 hours after administration of oral labetalol. Oral clearance of labetalol decreased with cimetidine administration (58.7 +/- 23.3 to 32.9 +/- 13.2 ml/min/kg; p less than 0.05), thereby causing a 79% increase in area under the curve. Labetalol systemic clearance also decreased (23.2 +/- 5.3 to 17.7 +/- 3.7 ml/min/kg; p less than 0.05), but the volume of distribution was unchanged. Labetalol caused significant beta-blockade for 8 hours after the last oral dose, but cimetidine did not alter pharmacologic response. The Emax model provided a good description of the concentration-effect relationship. At peak labetalol concentrations after oral administration, (R,R)-labetalol concentrations were significantly lower than those of the other three stereoisomers (p less than 0.05). Cimetidine caused an increase in the concentrations of each stereoisomer, but the difference was significant (p less than 0.05) for only the (S,R)-, (S,S)-, and (R,S)-isomers. This first evidence of labetalol stereoselective disposition is consistent with the findings of previous (R,R)-labetalol pharmacokinetic studies and with previous pharmacodynamic investigations of labetalol and (R,R)-labetalol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225711     DOI: 10.1038/clpt.1990.187

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.

Authors:  Sze Wa Chan; Miao Hu; Sara Shun Wah Ko; Catherine Wing Yan Tam; Benny Siu Pong Fok; Ophelia Qi Ping Yin; Moses Sing Sum Chow; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

2.  Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.

Authors:  K M Chu; S M Shieh; O Y Hu
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Relationship among physicochemical properties, skin permeability, and topical activity of the racemic compound and pure enantiomers of a new antifungal.

Authors:  L Wearley; B Antonacci; A Cacciapuoti; S Assenza; I Chaudry; C Eckhart; N Levine; D Loebenberg; C Norris; R Parmegiani
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

4.  Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients.

Authors:  Teresa Maria J P Carvalho; Ricardo de Carvalho Cavalli; Sérgio P Cunha; Cláudia O de Baraldi; Maria P Marques; Natalícia J Antunes; Ana Leonor P C Godoy; Vera Lucia Lanchote
Journal:  Eur J Clin Pharmacol       Date:  2010-09-17       Impact factor: 2.953

Review 5.  Clinical experience with dual-acting drugs in hypertension.

Authors:  K H Rahn
Journal:  Clin Investig       Date:  1992

6.  Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.

Authors:  James H Fischer; Gloria E Sarto; Jennifer Hardman; Loraine Endres; Thomas M Jenkins; Sarah J Kilpatrick; Hyunyoung Jeong; Stacie Geller; Kelly Deyo; Patricia A Fischer; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

7.  Combined alpha/beta-blockade: an underused approach to the treatment of resistant hypertension.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-09       Impact factor: 3.738

8.  Towards precision critical care management of blood pressure in hemorrhagic stroke patients using dynamic linear models.

Authors:  Yuzhe Liu; Jody Manners; Yazan Bittar; Sherry H-Y Chou; Vanathi Gopalakrishnan
Journal:  PLoS One       Date:  2019-08-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.